METHODS, CELLS AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS
    2.
    发明申请
    METHODS, CELLS AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS 有权
    将非经典氨基酸掺入蛋白质的方法,细胞和系统

    公开(公告)号:US20120237971A1

    公开(公告)日:2012-09-20

    申请号:US13353106

    申请日:2012-01-18

    CPC分类号: C12N15/67

    摘要: The present disclosure pertains to methods of incorporating one or more non-canonical amino acids into a protein during a translation of the protein in bacterial cells. The present disclosure also pertains to methods of incorporating one or more non-canonical amino acids into a protein during an in vitro translation of the protein. In additional embodiments, the present disclosure pertains to isolated bacterial cells and in vitro translation systems (e.g., cell-free extract systems) for incorporating one or more non-canonical amino acids into a protein during a translation of the protein.

    摘要翻译: 本公开涉及在蛋白质在细菌细胞中翻译期间将一种或多种非标准氨基酸掺入蛋白质的方法。 本公开还涉及在体外翻译蛋白质期间将一种或多种非标准氨基酸掺入蛋白质的方法。 在另外的实施方案中,本公开涉及在翻译蛋白质期间将一种或多种非标准氨基酸掺入到蛋白质中的分离的细菌细胞和体外翻译系统(例如,无细胞提取系统)。

    PREPARATION AND USE OF COMPOUNDS AS PROTEASE INHIBITORS
    6.
    发明申请
    PREPARATION AND USE OF COMPOUNDS AS PROTEASE INHIBITORS 审中-公开
    化合物作为蛋白酶抑制剂的制备和使用

    公开(公告)号:US20140206715A1

    公开(公告)日:2014-07-24

    申请号:US14226338

    申请日:2014-03-26

    IPC分类号: C07D471/04

    摘要: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Q is a bond or —N(R5)—; T is a bond, —O—, —C(O)—; S, —N(R5)—, or —C(R6′R7′); U is a bond or —C(R6)(R7)— Y is C or N; Z is C or N; ring A, including variables Y and Z, is a three to nine membered cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, and heteroaryl ring having 0 to 4, preferably 0 to 2, heteroatoms independently selected from the group consisting of O, S, N and —N(R)—, wherein ring A is unsubstituted or substituted with 1 to 5 independently selected R1 moieties and/or oxo when ring A is cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl; and R, R1, R2, R3, R4, R5, R6, R6, R7 and R7′ are as defined in the specification; pharmaceutical compositions comprising the compounds of formula I and the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases.

    摘要翻译: 公开了式I化合物或其立体异构体,互变异构体或其药学上可接受的盐或溶剂合物,其中Q是键或-N(R 5) - ; T是键,-O - , - C(O) - ; S,-N(R 5) - 或-C(R 6'R 7'); U是键或-C(R6)(R7)-Y是C或N; Z是C或N; 环A包括变量Y和Z是具有0至4个,优选0至2个杂原子的3至9元环烷基,环烯基,杂环基,杂环烯基,芳基和杂芳基环,其独立地选自O,S, N和-N(R) - ,其中当环A是环烷基,环烯基,杂环基或杂环烯基时,环A是未取代的或被1至5个独立选择的R 1部分和/或氧代取代。 并且R,R 1,R 2,R 3,R 4,R 5,R 6,R 6,R 7和R 7'如本说明书中所定义; 包含式I化合物的药物组合物和抑制天冬氨酰蛋白酶的方法,特别是治疗心血管疾病,认知和神经变性疾病的方法。

    Substituted isoindolines as aspartyl protease inhibitors
    7.
    发明授权
    Substituted isoindolines as aspartyl protease inhibitors 有权
    取代的异吲哚啉作为天冬氨酰蛋白酶抑制剂

    公开(公告)号:US08722708B2

    公开(公告)日:2014-05-13

    申请号:US11451065

    申请日:2006-06-12

    摘要: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Q is a bond or —N(R5)—; T is a bond, —O—, —C(O)—; S, —N(R5)—, or —C(R6′R7′); U is a bond or —C(R6)(R7)— Y is C or N; Z is C or N; ring A, including variables Y and Z, is a three to nine membered cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, and heteroaryl ring having 0 to 4, preferably 0 to 2, heteroatoms independently selected from the group consisting of O, S, N and —N(R)—, wherein ring A is unsubstituted or substituted with 1 to 5 independently selected R1 moieties and/or oxo when ring A is cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl; and R, R1, R2, R3, R4, R5, R6, R6, R7 and R7′ are as defined in the specification; pharmaceutical compositions comprising the compounds of formula I and the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases.

    摘要翻译: 公开了式I化合物或其立体异构体,互变异构体或其药学上可接受的盐或溶剂合物,其中Q是键或-N(R 5) - ; T是键,-O - , - C(O) - ; S,-N(R 5) - 或-C(R 6'R 7'); U是键或-C(R6)(R7)-Y是C或N; Z是C或N; 环A包括变量Y和Z是具有0至4个,优选0至2个杂原子的3至9元环烷基,环烯基,杂环基,杂环烯基,芳基和杂芳基环,其独立地选自O,S, N和-N(R) - ,其中当环A是环烷基,环烯基,杂环基或杂环烯基时,环A是未取代的或被1至5个独立选择的R 1部分和/或氧代取代。 并且R,R 1,R 2,R 3,R 4,R 5,R 6,R 6,R 7和R 7'如本说明书中所定义; 包含式I化合物的药物组合物和抑制天冬氨酰蛋白酶的方法,特别是治疗心血管疾病,认知和神经变性疾病的方法。

    Sub-frame tapered reset
    10.
    发明授权
    Sub-frame tapered reset 有权
    子框架锥形复位

    公开(公告)号:US08488025B2

    公开(公告)日:2013-07-16

    申请号:US12582316

    申请日:2009-10-20

    IPC分类号: H04N5/217 H04N5/335

    摘要: Systems and methods are provided that facilitate employing a plurality of independent reset buses for a column of pixels in a pixel array of a CMOS sensor imager. Utilization of the plurality of independent reset buses for the column of pixels can enable independent reset to be effectuated when employing sub-frame integration. For example, rows to be read and reset during a given readout time interval can be selected based upon one or more criteria. Further, each of the rows selected during the given readout time interval can be associated with a respective distinct reset bus. By leveraging the plurality of independent reset buses, uniformity in pixel operation can be maintained whether operating in full frame integration mode or sub-frame integration mode. Thus, noise resultant from changing between integration modes can be mitigated by using the plurality of independent reset buses.

    摘要翻译: 提供了系统和方法,其便于对CMOS传感器成像器的像素阵列中的像素列采用多个独立的复位总线。 对于像素列,多个独立复位总线的利用可以使得在采用子帧集成时能够实现独立的复位。 例如,可以基于一个或多个标准来选择在给定的读出时间间隔期间要读取和复位的行。 此外,在给定读出时间间隔期间选择的每行都可以与相应的不同的复位总线相关联。 通过利用多个独立的复位总线,无论是在全帧集成模式还是子帧集成模式下操作,都可以保持像素操作的均匀性。 因此,可以通过使用多个独立复位总线来减轻由积分模式之间变化引起的噪声。